USPTO serial 88570483
X PARSOLEX PARTNER SOLUTIONS EXCELLENCE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 18, 2021
- Examiner
- BULLOFF, TOBY ELLEN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with X PARSOLEX PARTNER SOLUTIONS EXCELLENCE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
West Lafayette, IN, US
West Lafayette, IN, US
West Lafayette, IN, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jill J. Chalmers
Jill J. Chalmers BRYAN CAVE LEIGHTON PAISNER LLP90 SOUTH CASCADE AVENUE, SUITE 1300COLORADO SPRINGS, CO 80903UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Consulting services in the fields of pharmaceutical, medical and healthcare research and development; technical services, namely, research and development in the pharmaceutical and biotechnology fields; consulting services for pharmaceutical formulation design, design of processes to transform inorganic and organic substances and pharmaceutical technology transfer being advice and information about pharmaceutical research and design; technical services, namely, providing advice, information and instructions for pharmaceutical formulation design and design of processes to transform inorganic and organic substances, pharmaceutical technology transfer being advice and information about pharmaceutical research and design; pharmaceutical product chemical and physical evaluation services, namely, test method development, test method validation, use of test methods for in-process control, quality control, and product release, and technology transfer being advice and information about pharmaceutical test methods; analytical chemistry services, namely, developing and validating test methods for drug product release; technology transfer being advice and information about the drug product testing process and test methods; providing services to others in the fields of analytical, chemistry and manufacturing controls for the production and regulatory approval of pharmaceuticals, namely, providing scientific information relating to the analysis and management of the pharmaceutical manufacturing process for the production, packaging, and regulatory approval of pharmaceuticals; consulting services in the fields of chemistry, biotechnology, pharmaceutical research and development, laboratory testing, and diagnostics; consulting and research and development services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; technical consulting in the fields of pharmaceutical studies, research and development; technical consulting in the field of pharmaceutical development and engineering; technical consulting in the field of analytical chemistry services; consultancy pertaining to pharmacology; technology consultation in the fields of research and development of pharmaceuticals, medicines and healthcare products; scientific research consulting in the fields of pharmaceuticals, medicines and healthcare products; product development consulting in the fields of pharmaceuticals, medicines and healthcare products; scientific research services relating to pharmaceuticals, medicines and healthcare products; product development consultation; product development services; formulation and process design services for drug products for others; outsource service provider for manufacturing and packaging of pharmaceuticals; formulation and process design services for drug products for others; design of packaging for pharmaceuticals of others; pharmaceutical product packaging design services for others; formulation and process design services for drug products of others; provision of information, advice and consultancy in relation to pharmaceutical packaging design; technical consulting in the field of pharmaceutical research and development; custom pharmaceutical service provider, namely, pharmaceutical formulation design, design of processes to transform inorganic and organic substances, and chemical and physical evaluation of pharmaceuticals; consulting in the areas of pharmaceutical formulation design, design of processes to transform inorganic and organic substances, and chemical and physical evaluation of pharmaceuticals; development of custom pharmaceuticals for others; design of packaging for pharmaceuticals for others; formulation and process design services for drug products for others | ACTIVE | Oct 28, 2019 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Parsolex GMP Center, Inc.
- Other trademarks owned by Parsolex GMP Center, Inc.
- Other trademarks owned by Parsolex GMP Center, Inc.
- Other trademarks in Class 042
- Similar marks named X PARSOLEX PARTNER SOLUTIONS EXCELLENCE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 18, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 18, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 16, 2021 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Apr 15, 2021 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Apr 2, 2021 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Apr 1, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 17, 2021 | IUAF | USE AMENDMENT FILED | — |
| Mar 17, 2021 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Sep 22, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 28, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 28, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 8, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 24, 2020 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 16, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 16, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 16, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 16, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 16, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 16, 2020 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jun 15, 2020 | ISMR | WITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST | — |
| May 26, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 26, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 6, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 22, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 22, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 22, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 22, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 22, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 16, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 16, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 15, 2020 | ALIE | ASSIGNED TO LIE | — |
| Apr 8, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 31, 2019 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 31, 2019 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 31, 2019 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 16, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 27, 2019 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 24, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 10, 2019 | NWAP | NEW APPLICATION ENTERED | — |